Yazar "Sirekbasan, Serhat" seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Çocukluk yaş grubu gastroenteritlerinde rotavirüs ve adenovirüs sıklığı: Ocak 2013-Aralık 2018 Cerrahpaşa Tıp Fakültesi verileri(2019) Dinç, Harika Öykü; Taner, Zeynep; Özbey, Doğukan; Gareayaghi, Nesrin; Sirekbasan, Serhat; Kocazeybek, Bekir SamiAmaç: Gastroenterit kuşkusu ile laboratuvarımıza Ocak 2013-Aralık 2018 yılları arasında rotavirüs ve adenovirüs antijen testi istenen hastalarda dışkı örneğinden antijen pozitifliğinin dağılımı ve demografik verilerle ilişkisinin retrospektif değerlendirilmesi amaçlanmıştır. Yöntem: Rotavirüs ve adenovirüs antijen varlığı dışkı örneklerinden immünokromatografik yöntem testi (RIDA Quick Rotavirüs/Adenovirus Combi, T-Biopharm, Almanya) kullanılmış olup, ticari kitin önerileri doğrultusunda çalışıldı. Bulgular: Çocuklarda 0-5 yaş arası 1.359 kişide rotavirüs, 1.270 kişide adenovirüs antijen taraması yapıldı. Test uygulanan tüm dışkı örneklerinin 194 (%14.3)’ünde rotavirüs antijeni, 39 (%3.1)’unda adenovirüs antijeni saptandı. Rotavirüs antijen pozitifliği en sık 0-1 yaş (n=141, %72.7) grubunda olup, mevsimsel olarak en sık kış aylarında saptandı. Adenovirüs antijen pozitifliği ise 0-24 ay yaş grubu (n=20, %51.3) arasında saptanmış olup, kış mevsimlerinde sık dağılım söz konusudur. Sonuç: Çocuklarda gastroenterit etkeni olarak en sık görülen rotavirüs, merkezimizden önceki döneme ait yapılan çalışmaya göre daha düşük oranda saptanmıştır. Adenovirüs ise; Türkiye’nin diğer bölgeleriyle aynı orana sahiptirÖğe Evaluation of the diagnostic performance of different principles of SARS-CoV-2 commercial antibody tests in COVID-19 patients(Ankara Microbiology Society, 2021) Dinç, Harika Öykü; Özdemir, Yusuf Emre; Alkan, Sena; Dalar, Zeynep Güngördü; Gareayaghi, Nesrin; Sirekbasan, Serhat; Kocazeybek, Bekir; Tuyji Tok, Yeşim; Kuşkucu, Mert Ahmet; Karaali, Rıdvan; Özbey, Doğukan; Aygün, Gökhan; Midilli, KenanFollowing the emergence of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) and using only PCR for diagnosis, antibody tests have been rapidly developed by various commercial companies. There are differences between the sensitivity and specificity of these tests due to the usage of different viral target proteins and antibody subclasses. In order to evaluate the diagnostic use of these tests, we aimed to examine the diagnostic performance, especially sensitivity and specificity, of SARS-CoV-2 IgM, IgA and IgG tests of various companies (Abbott, Roche, Euroimmun, Dia.Pro, Anshlabs, Vircell, UnScience and RedCell), which have different principles (ECLIA/CLIA, EIA, LFA). Current (n= 180) and past (n= 180) COVID-19 patients with clinical and molecular diagnosis of COVID-19 admitted to Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine Hospital, Pandemic Polyclinic with suspected COVID-19 infection, were included in our study. The patients admitted within the first 3 weeks after the onset of symptoms were included in the current patient group, and those admitted at the third and after the third week were included in the past patient group. Serum samples (n= 180) obtained from Istanbul Sisli Hamidiye Etfal Training and Research Hospital, Blood Center between April and June 2018 before the COVID-19 pandemic were included in the study as a control group. All the tests included in our study were studied with the recommendations of the manufacturer companies. Between the IgG detection tests with different principles in patients with past COVID-19, the sensitivity and specificity values of the most effective tests were; 86.7%/99.4% (Abbott), 86.1%/98.9% (Dia.Pro), 91.3%/95% (RedCell). Between the IgM detection tests with different principles in current COVID-19 patients, the sensitivity and specificity values were; 67.8%/99.4% (Abbott), 68.9%/98.6% (Vircell), 50%/97.5% (RedCell). Abbott IgM with a kappa coefficient of 0.67 and Vircell IgM + IgA test with a kappa coefficient of 0.65 showed the best fit in patients with current COVID-19 infection. In patients with past COVID-19, Abbott IgG with 0.86 kappa coefficient and Dia.Pro IgG test with 0.85 kappa coefficient showed the best match. Due to the low sensitivity of IgM detection antibody tests, they should not be preferred instead of real-time reverse transcriptase polymerase chain reaction in routine diagnosis. IgG detection tests may be preferred to detect the antibody response and the titers in people who have had COVID-19 for population seroprevalence and especially therapeutic immune plasma production. However, it is thought that the combined use of both ECLIA/CLIA-based and EIA/ELISA-based tests together may be more effective in routine use for SARS-CoV-2 IgG tests. © 2021 Ankara Microbiology Society. All rights reserved.Öğe Morphological changes of trichomonas vaginalis treated by ornidazole: An in-vitro study(Clin Lab Publ, 2016) Çakan, Hüseyin; Polat, Erdal; Arda, Oktay; Cepni, İsmail; Dirican, Ahmet; Sirekbasan, SerhatBackground: Nitroimidazoles, which are drugs that are used to effectively treat Trichomonas vaginalis, alter the structure of the T. vaginalis cell membrane, penetrate into its cytoplasm and nucleus and block cellular metabolism. In this study, we observed the morphological changes that occurred in T. vaginalis during in vitro exposure to 1.3 mu g/mL of ornidazole at various time intervals ranging from 10 minutes to 10 hours. Methods: Vaginal and urethral secretion samples from suspected T. vaginalis cases were inoculated into Cysteine Peptone Liver Maltose medium. In 18 sterile tubes, 9.5 mL of this solution were mixed with 0.5 mL of ornidazole. The periods of contact between ornidazole and T. vaginalis ranged from 10 minutes to 10 hours. Results: The first change was vacuolization, which started in the 10th minute of exposure. The glycogen particles started to diminish in the 20th minute. Conclusions: During exposure to 1.3 mg/L of ornidazole, cell lysis began in the 30th minute and accelerated towards the 60th minute (p < 0.001). Cytoplasmic matrix integrity was impaired in the 60th minute (p < 0.001).